Abstract:© Arnold 1998 0267–6591(98)PM167ED The modern hospice and palliative care movement developed during the 1960s and 1970s as a response to the unmet needs of terminally ill patients and their families.1 This British initiative soon became an international endeavour. Regular local, national and international meetings, six peerreviewed journals and a comprehensive multiauthored textbook provide evidence of the increasing body of knowledge in the field.2 Palliative care is currently provided in multiple settings, including acute care hospitals, cancer centres, hospices and at home by an increasing number of health care professionals. Palliative care, however, has only been partially successful in two areas. One is the integration with academic medicine. As a result, undergraduate and postgraduate palliative medicine education is either not available or is insufficient in most medical schools around the world, although a number of curricula have been produced.3 In addition, palliative care clinicians have major difficulties in conducting research without the methodological support available to academic physicians.4 The second problem area is the partial insertion of palliative care programmes within the health care system. This has made funding difficult for programmes and professionals, and has limited patient and family access to palliative care services. The lack of complete integration within the health care system is concerning because of the expected increase in the number of cancer deaths of 50% and 70% in developed and developing countries respectively during the next decade, and the general ageing of the world population.5 If the number of available programmes and professionals does not increase accordingly, access to palliative care will progressively decrease. In times of decreasing health care budgets worldwide, maintaining or expanding existing programmes requires palliative care to demonstrate that it can improve specific clinical outcomes in patients and families. In other words, does palliative care work? Is it better for patients and their families to receive palliative care as compared to conventional care? The great majority of those working in palliative care would feel that it is obvious that palliative care is effective. However, a recent systematic review of palliative cancer care identified a minimal number of published studies.6 Both patient populations and the nature of the palliative interventions were poorly defined in such studies. In addition, the outcome measures were very different, making the comparison of results difficult. These findings therefore suggest that we need better effectiveness studies. Palliative care also needs to show how the cost of our interventions compares with conventional care. Economic evaluations of health care have traditionally attempted to establish differences in costs of interventions assumed to be of identical efficacy in all relevant aspects (cost-minimization analysis) or of interventions that are likely to have different outcomes (cost effectiveness, cost-benefit, and cost-utility analysis).7 The latter have been used in the economic evaluation of interventions such as renal or cardiac transplantation, screening of prostate or breast cancer, and immunizations. The effectiveness outcomes of such economic evaluations include quality-adjusted life-years, lifeyears gained, disability days saved, etc. It has been suggested that the threshold value ranges from $20 000 to $100 000 (Canadian dollars) per qualityadjusted life-year.8 These effectiveness outcomes are inappropriate for economic evaluations in palliative care. It is, therefore, important to define patient, family, and society related benefits of palliative care interventions that can be used in economic evaluations. Editorial

Aggregation-induced electrochemiluminescence based on intramolecular charge transfer and twisted molecular conformation for label-free Immunoassay

Aggregation-Induced Enhanced Electrochemiluminescence Resonance Energy Transfer Biosensor for Ultrasensitive Detection of Carcinoembryonic Antigen Based on Donor-Acceptor Organic Nanoparticles

Coreactant-free aggregation-induced electrochemiluminescence system based on the novel zinc-luminol metal-organic gel for ultrasensitive detection of PiRNA-823

Strong aggregation-induced electrochemiluminescence of pyrene-coordination metal-organic frameworks coupled with zero-valent iron as novel accelerator for ultrasensitive immunoassay

Dual amplification electrochemiluminescence of carbonized polymer dots embedded in the metal-organic framework with low trigger potential and nanoconfinement enhancement for sensitive CYFRA21-1 immunoassay

Label-free immunosensor for cardiac troponin I detection based on aggregation-induced electrochemiluminescence of a distyrylarylene derivative

Electrochemiluminescence Sensing Platform Based on Functionalized Poly-(Styrene-co-maleicanhydride) Nanocrystals and Iron Doped Hydroxyapatite for CYFRA 21-1 Immunoassay

Cost effectiveness in palliative care

Ratiometric electrochemiluminescent strategy regulated by electrocatalysis of palladium nanocluster for immunosensing.

Potential-Resolved Multicolor Electrochemiluminescence for Multiplex Immunoassay in a Single Sample.

Aggregation-Induced Electrochemiluminescence Bioconjugates of Apoferritin-Encapsulated Iridium(III) Complexes for Biosensing Application.

Dumbbell Plate‐Shaped AIEgen‐Based Luminescent MOF with High Quantum Yield as Self‐Enhanced ECL Tags: Mechanism Insights and Biosensing Application

Recent Advances in Aggregation-Induced Electrochemiluminescence

Electrochemiluminescence Lateral Flow Immunoassay Using Ruthenium(II) Complex‐Loaded Dendritic Mesoporous Silica Nanospheres for Highly Sensitive and Quantitative Detection of SARS‐CoV‐2 Nucleocapsid Protein

Near-Infrared Electrochemiluminescence of Dual-Stabilizer-Capped Au Nanoclusters for Immunoassays

Intramolecular Coreaction Accelerated Electrochemiluminescence of Polypeptide-Biomineralized Gold Nanoclusters for Targeted Detection of Biomarkers.

Porphyrins-mediated interfacial charge modulation to enhance aggregation-induced electrochemiluminescence of iridium complex for ultrasensitive bioassay

An efficient aggregation-induced electrochemiluminescent immunosensor by using TiO2 nanoparticles as coreaction accelerator and energy donor for aflatoxin B1 detection

Hexagon AgNCs/PVP Crystallization Induced Cathode Electrochemiluminescence Enhancement for miRNA221 Biosensing

Electrochemiluminescence nanoemitters for immunoassay of protein biomarkers

Tetraphenylethylene-Functionalized Metal–Organic Frameworks with Strong Aggregation-Induced Electrochemiluminescence for Ultrasensitive Analysis through a Multiple Convertible Resonance Energy Transfer System